Tuttle: AVGO "Almost Needs Cure for Cancer" to Justify Valuation

Matt Tuttle considers Broadcom (AVGO) a "must own" A.I. chip stock, alongside Nvidia (NVDA). He'll focus on the company's margins and VMware, believing they serve as indicators for Broadcom's future growth. That said, Matt is nervous when it comes to valuation, arguing that Broadcom "almost needs to have a cure for cancer" for the stock to push higher. Tom White offers a pair of example options trades for the chipmaker.

======== Schwab Network ========

Empowering every investor and trader, every market day.

Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribe

Download the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185

Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7

Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watch

Watch on Vizio - https://www.vizio.com/en/watchfreeplus-explore

Watch on DistroTV - https://www.distro.tv/live/schwab-network/

Follow us on X – https://twitter.com/schwabnetwork

Follow us on Facebook – https://www.facebook.com/schwabnetwork

Follow us on LinkedIn - https://www.linkedin.com/company/schwab-network/

About Schwab Network - https://schwabnetwork.com/about